Human Herpesvirus 8 in Healthy Blood Donors, Argentina by Pérez, Celeste L. et al.
LETTERS
was positive. No other pathogens were 
detected in her blood, urine, sputum, 
bronchoalveolar lavage, or thoracen-
thesis ﬂ  uid.
Empiric treatment in patients with 
pandemic (H1N1) 2009 should be con-
sidered in those seeking treatment for 
inﬂ  uenza-like symptoms, especially in 
the setting of sick contacts with respi-
ratory illnesses. Rapid inﬂ  uenza tests, 
respiratory ﬂ  uorescent antibody tests, 
and viral cultures may not provide a 
diagnosis. An RT-PCR for pandemic 
(H1N1) 2009 may be needed to pro-
vide a diagnosis.
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Human Herpesvirus 
8 in Healthy Blood 
Donors, Argentina
To the Editor: Human herpesvi-
rus 8 (HHV-8), or Kaposi sarcoma–
associated herpesvirus, is associated 
with malignant disorders such as 
Kaposi sarcoma, primary effusion 
lymphoma, and multicentric Castle-
man disease. Although HHV-8 does 
not necessarily cause life-threatening 
infection in healthy persons, it causes 
more severe infection in those who 
are immunocompromised, such as 
organ recipients and HIV-infected 
persons.
HHV-8 has been found in a num-
ber of clinical specimens (blood, sa-
liva, and semen) from persons with 
HHV-8 related diseases (1,2). Identi-
ﬁ  cation of infectious virus in lympho-
cytes from a healthy blood donor and 
evidence that HHV-8 might be trans-
mitted by blood has raised concern 
about the safety of the blood supply 
(3,4). Few studies have detected vi-
ral DNA in blood samples of blood 
donors from areas with low HHV-8 
prevalence (5–7). During January 
2000 and December 2002, the Virol-
ogy Department, National Institute of 
Infectious Diseases, Administración 
Nacional de Laboratorios e Insti-
tutos de Salud, “Dr C G. Malbrán” 
conducted an HHV-8 serosurvey of 6 
blood banks from 5 South American 
regions and found overall seropreva-
lence to be 3.7% (range 1.9%–6.7%). 
The 6.7% seroprevalence from a 
blood bank in Buenos Aires city was 
substantially higher than that of other 
blood banks (8).
From July 2004 through January 
2005, to look for the virus in blood 
and saliva, we conducted the study 
reported here, an HHV-8 survey at 
the same blood bank. A total of 577 
volunteer blood donors (431 men 
and 146 women), mean age 39 years 
(range 17–76 years), were enrolled 
at the Hemotherapy Service, Hospi-
tal of Infectious Diseases “Francisco 
Javier Muñiz.” The protocol was ap-
proved by the Teaching and Research 
Committee. 
Serum and whole blood were col-
lected from all 577 donors, and paired 
blood–saliva samples were obtained 
from 394. Serum samples were rou-
tinely tested for hepatitis B and C 
viruses, HIV, human T-lymphotropic 
viruses I and II, Treponema pallidum, 
Brucella spp., and Trypanosoma cru-
zi; results were used to determine as-
sociations between HHV-8 and these 
agents. Specimens were stored at 
–20°C until serologic and molecular 
investigation at the Virology Depart-
ment, National Institute of Infectious 
Diseases. 
Serologic screening for HHV-8 
infection was performed by indirect 
immunoﬂ   uorescence assay by using 
lytically induced cells; serum samples 
were diluted 1:40 (8). Then 45 blood 
and 39 paired blood–saliva samples 
from HHV-8-seroreactive donors were 
investigated for viral genome by open 
reading frame 26 nested PCR. DNA 
was puriﬁ  ed from 0.3 mL of whole 
blood by using FlexiGene DNA Kit 
(QIAGEN, Gmbh, Hilden, Germa-
ny); concentrations and quality were 
measured with a UV spectrophotom-
eter, and 1 μg was used for PCR. The 
QIAamp DNA Mini Kit (QIAGEN, 
Gmbh,) was used to obtain DNA from 
0.2-mL saliva samples. Crude pel-
lets were resuspended in 20μL of Tris 
EDTA, pH 8, then 5 μL were added 
to the PCR. Quality of DNA isolated 
from negative PCR samples was test-
ed by amplifying the human house-
keeping gene β-globin. In addition, 
inhibitors were investigated by add-
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ing the minimum viral DNA amount 
detected by our nested PCR, previ-
ously assessed by 10-fold serial dilu-
tions of DNA from body cavity–based 
lymphoma 1 cells. The results are 
expressed as percentages, 95% conﬁ  -
dence intervals (CIs), and proportions 
(positive/total). When necessary, the 
associations between variables were 
tested by means of χ2 or logistic re-
gression. Signiﬁ  cance was deﬁ  ned as 
p<0.05. Data were analyzed by using 
the Epidat 3.0 program, available from 
www.paho.org.
Positive  immunofluorescence 
assay results were obtained for 45 
(7.79%) of the 577 blood donors; 
seroprevalence was independent of 
gender (p = 0.8) and increased with 
age (odds ratio 1.04, 95% CI 1.01–
1.07, p = 0.028). No association was 
found between HHV-8 and seroreac-
tivity to the infectious agents tested 
(p = 0.3438). HHV-8 DNA was found 
in 3 seroreactive blood donors: 1 in 
saliva only and 2 in blood and sa-
liva. Of the 45 HHV-8 seropositive 
samples, 38 were nonreactive to any 
infectious agents tested in the blood 
bank. One donor was seroreactive for 
hepatitis B. 
In summary, we found HHV-8 
in blood and saliva of blood donors 
even in an area where the virus is not 
endemic. Seroprevalence for HHV-8 
was similar to that previously reported 
(8). Also, low viral loads might be un-
detectable by PCR but high enough to 
cause an infection with usual volumes 
of blood used in transfusions (9), es-
pecially when the hemoderivatives 
are given to immunocompromised 
recipients. This study was done in a 
blood bank from a hospital for infec-
tious diseases in which the recipient 
population consisted of numerous 
HIV patients (10). It is a concern that 
these patients could have received 
blood infected with HHV-8. The fact 
that saliva samples were also positive 
is consistent with previously reported 
ﬁ  ndings (1,2) and might indicate that 
the virus is active at a site from which 
samples are easier to obtain and in 
which the virus easier to detect than 
the bloodstream. This study provides 
further evidence that blood transfu-
sion carries a potential risk for HHV-8 
infection, even in areas where its prev-
alence is low.
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Letters
Letters commenting on recent articles 
as well as letters reporting cases, 
outbreaks, or original research are 
welcome. Letters commenting on ar-
ticles should contain no more than 
300 words and 5 references; they are 
more likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
outbreaks, or original research should 
contain no more than 800 words and 
10 references. They may have 1 
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.